Overview A Study to Evaluate the Efficacy and Safety of AD-223 Status: COMPLETED Trial end date: 2025-04-02 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of AD-223Phase: PHASE3 Details Lead Sponsor: Addpharma Inc.